TW202245805A - 腺苷衍生物及包含其之醫藥組合物 - Google Patents

腺苷衍生物及包含其之醫藥組合物 Download PDF

Info

Publication number
TW202245805A
TW202245805A TW111103173A TW111103173A TW202245805A TW 202245805 A TW202245805 A TW 202245805A TW 111103173 A TW111103173 A TW 111103173A TW 111103173 A TW111103173 A TW 111103173A TW 202245805 A TW202245805 A TW 202245805A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
bond
alkenyl
cycloalkyl
Prior art date
Application number
TW111103173A
Other languages
English (en)
Chinese (zh)
Inventor
連紅 徐
Original Assignee
美商布里生物科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商布里生物科學股份有限公司 filed Critical 美商布里生物科學股份有限公司
Publication of TW202245805A publication Critical patent/TW202245805A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111103173A 2021-01-25 2022-01-25 腺苷衍生物及包含其之醫藥組合物 TW202245805A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163141450P 2021-01-25 2021-01-25
US63/141,450 2021-01-25

Publications (1)

Publication Number Publication Date
TW202245805A true TW202245805A (zh) 2022-12-01

Family

ID=82494279

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111103173A TW202245805A (zh) 2021-01-25 2022-01-25 腺苷衍生物及包含其之醫藥組合物

Country Status (12)

Country Link
US (2) US11793827B2 (https=)
EP (1) EP4281081A4 (https=)
JP (1) JP7843289B2 (https=)
KR (1) KR20230132476A (https=)
CN (1) CN116710465A (https=)
AU (1) AU2022210781A1 (https=)
CA (1) CA3202049A1 (https=)
IL (1) IL304366A (https=)
MX (1) MX2023008004A (https=)
TW (1) TW202245805A (https=)
WO (1) WO2022159872A1 (https=)
ZA (1) ZA202408803B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
EP4281081A4 (en) 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
CR20250310A (es) * 2023-01-30 2025-08-25 Merck Sharp & Dohme Llc Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3407191A (en) * 1966-08-29 1968-10-22 Lilly Co Eli Adamantoate esters of nucleosides
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2007022073A2 (en) 2005-08-12 2007-02-22 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
MX391226B (es) * 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
US20180030080A1 (en) * 2016-07-28 2018-02-01 Alexandre Vasilievich Ivachtchenko Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
RU2659388C1 (ru) * 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
DK3590924T3 (da) 2017-02-28 2022-01-03 Kangpu Biopharmaceuticals Inc Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf
US20190185508A1 (en) * 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
EP3762396A1 (en) 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
CN109053803A (zh) 2018-07-04 2018-12-21 米文君 一类新的化合物及其用途
AU2019317810A1 (en) * 2018-08-09 2021-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2021038509A1 (en) 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
KR20220066303A (ko) 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
EP4281081A4 (en) 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS

Also Published As

Publication number Publication date
US12390484B2 (en) 2025-08-19
KR20230132476A (ko) 2023-09-15
AU2022210781A9 (en) 2024-10-10
US20220233567A1 (en) 2022-07-28
EP4281081A1 (en) 2023-11-29
ZA202408803B (en) 2025-06-25
JP2024503723A (ja) 2024-01-26
IL304366A (en) 2023-09-01
CN116710465A (zh) 2023-09-05
EP4281081A4 (en) 2025-05-14
JP7843289B2 (ja) 2026-04-09
US11793827B2 (en) 2023-10-24
MX2023008004A (es) 2023-07-13
CA3202049A1 (en) 2022-07-28
WO2022159872A1 (en) 2022-07-28
US20240245716A1 (en) 2024-07-25
AU2022210781A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
TWI862645B (zh) 腺苷衍生物及包含其之醫藥組合物
TW202245805A (zh) 腺苷衍生物及包含其之醫藥組合物
JP6563585B2 (ja) 抗ウイルス性ベータ−アミノ酸エステルホスホジアミド化合物
EP3503895B1 (en) Antiviral prodrugs of tenofovir
JP2022525013A (ja) Ｈｉｖ療法において有用な化合物
US20210323993A1 (en) Compounds Useful in HIV Therapy
TW201302761A (zh) Ｈｉｖ抑制劑之固態形式
TWI415851B (zh) ２-（經取代-胺基）-苯并噻唑磺醯胺之ｈｉｖ蛋白酶抑制劑
CN116801884B (zh) 使用腺苷衍生物和衣壳抑制剂的针对hiv的组合疗法
TW202023650A (zh) 用於治療hiv之化合物
US8513205B2 (en) Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
JP2021515771A (ja) Ｈｉｖ療法に有用な化合物
US11040975B2 (en) Carbocyclic nucleoside reverse transcriptase inhibitors
EA051612B1 (ru) Производное аденозина и содержащая его фармацевтическая композиция
RU2824528C2 (ru) Аденозиновое производное и фармацевтическая композиция, содержащая его
JP2010535202A (ja) ５’−置換アデノシン、その製造、及び、ｓ−アデノシルメチオニン脱炭酸酵素の阻害剤としての使用
UA80409C2 (en) Hexacyclic compounds
US20210260082A1 (en) Phosphinic amide prodrugs of tenofovir
HK40074714A (en) Adenosine derivative and pharmaceutical composition comprising the same
HK40074714B (zh) 腺苷衍生物和包含其的药物组合物
TW202517253A (zh) Cdk2抑制劑及其用途